Associated Papers
MET and NF2 alterations confer primary and early resistance to first-line alectinib treatment in ALK-positive non-small-cell lung cancer.
Hu J et al.
Molecular Oncology, 2025
40168046 (PubMed )
Supplement: MOL2-19-2715-s001.xlsx › Table_2
Select a paper to view details